— Know what they know.
Not Investment Advice

RAPP NASDAQ

Rapport Therapeutics, Inc. Common Stock
1W: -3.3% 1M: -0.2% 3M: +23.3% YTD: +30.6% 1Y: +259.1%
$37.72
+1.02 (+2.78%)
 
Weekly Expected Move ±7.8%
$31 $34 $37 $40 $43
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 56 · $1.4B mcap · 17M float · 1.95% daily turnover · Short 70% of daily vol

Cash Flow Trends

Operating Cash Flow
-$87M -34.9% ▼
Capital Expenditures
$616K +74.4% ▲
3Y CAGR: +29.4%
Free Cash Flow
-$88M -31.0% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$4M +68.8% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$11M-$35M-$78M-$111M
Depreciation & Amort.$16K$112K$839K$0
Stock-Based Comp.$610K$4M$10M$0
Change in Working Capital$1M$3M-$2M$0
Other Non-Cash Items$5M$1M$5M$24M
Operating Cash Flow-$3M-$27M-$65M-$87M
— Investing Activities —
Capital Expenditures-$284K-$2M-$2M$0
Acquisitions (Net)$0$0$0$0
Investment Purchases$0-$77M-$381M$0
Investment Sales$0$0$210M$0
Other Investing-$5M$0$3M-$187M
Investing Cash Flow-$5M-$79M-$170M-$187M
— Financing Activities —
Net Debt Issuance$8M$0$0$0
Stock Repurchased$0-$4K$0$0
Dividends Paid$0$0$0$0
Other Financing$0-$134K$7K$271M
Financing Cash Flow$40M$145M$222M$271M
Net Change in Cash$31M$39M-$13M-$4M
Cash End of Period$31M$70M$57M$53M
Free Cash Flow-$4M-$29M-$67M-$88M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms